{"id":2829,"date":"2025-07-25T17:43:53","date_gmt":"2025-07-25T09:43:53","guid":{"rendered":"https:\/\/mygenome.asia\/?page_id=2829"},"modified":"2025-08-20T12:05:40","modified_gmt":"2025-08-20T04:05:40","slug":"ddi-hdi","status":"publish","type":"page","link":"https:\/\/mygenome.asia\/zh\/ddi-hdi\/","title":{"rendered":"DDI \/ HDI"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t
<\/div>
<\/div>
Pharmaco-Interaction (PCI)<\/div>
MyGenome is currently the primary drug interaction service provider in this region<\/div><\/div><\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

MyGenome<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Pharmaco-Interaction\n(PCI)<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Drug-drug interactions (DDI) or herb-drug interactions (HDI) are a significant concern in healthcare as they could lead to serious adverse effects. MyGenome has now included in vitro testing for evaluation of potential risk for such interactions, with particular focus on cytochrome P450 enzyme inhibition.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Drug\/Herb Metabolism<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Drugs and other supplements undergo absorption, distribution, metabolism, and excretion processes inside the body. Metabolism is the most crucial step, where drugs are broken down into bioactive components for function or excretion.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\n\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Cytochrome P450s are crucial for Drug\/Herb Metabolism<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Cytochrome P450 enzymes (CYPs) act like factory workers in the liver to break down these compounds. There are eight major human CYP enzymes (CYP3A4, CYP2D6, CYP2C9, CYP1A2, CYP2C19, CYP2B6, CYP2C8, CYP2E1) responsible <\/span>for metabolizing 97%<\/strong> of drugs in the market.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

What is DDI or HDI?<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

When two or more drugs are taken concurrently, drug-drug interactions (DDI) could occur resulting in alteration of the concentration (pharmacokinetic changes) and\/or function (pharmacodynamic changes) of any of the drugs. Herbal products or supplements share the same metabolic processes. Many of these products contain bioactive compounds that could inhibit or induce the CYP enzymes, hence delaying or enhancing the drug metabolism process. This can affect the level of the drug in the body, potentially leading to ineffective therapeutic responses or adverse effects. The mechanism of drug-drug or herb-drug interaction (HDI) can be explained through the Drug Plasma Concentration graph.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

To be most effective, the plasma concentration of a drug should remain within the therapeutic range <\/span>(green)<\/span>.<\/b> At lower concentrations, the drug may not exert sufficient therapeutic response <\/span>(orange)<\/b><\/span>. At higher concentrations, it may cause toxicity or adverse effects <\/span>(red)<\/b><\/span>. Concurrent use of drug and herbal product could thus lead to low drug therapeutic response or higher risk of adverse effects. Below are examples of well-documented HDI:\u00a0<\/span><\/p>

We offer inhibition assays for the following CYP enzymes<\/i><\/b><\/p>

  1. CYP3A4\u00a0<\/span><\/li>
  2. CYP2C9\u00a0<\/span><\/li>
  3. CYP2D6\u00a0<\/span><\/li>
  4. CYP1A2\u00a0<\/span><\/li>
  5. CYP2B6\u00a0<\/span><\/li><\/ol>

    Test system<\/b>: <\/b> Human liver microsome<\/span><\/p>

    An<\/b>alysis Method:<\/i><\/b> Quantification using LC-MS\/MS following FDA regulatory guidelines<\/span><\/p>

    Customization<\/b>: <\/b> Tailored assay conditions <\/span>(please contact our service agents)<\/span><\/i><\/p>

    Data provided:<\/b> Inhibitory potential of your product (IC<\/span>50<\/span> value) in comparison with enzyme-specific standard inhibitor (FDA approved)\u00a0<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

    \n\t\t\t\t\t\t
    \n\t\t\t\t\t
    \n\t\t\t
    \n\t\t\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t

    Why Does CYP Inhibition Testing Matter?<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t\t\t\t\t

    If your product contains bioactive compounds or bioactive herbal components, there is a likelihood that your product could interact with specific drug metabolism. Identifying CYP inhibition\/induction potential is critical for:<\/span><\/p>